163 related articles for article (PubMed ID: 23759796)
1. Is mipomersen ready for clinical implementation? A transatlantic dilemma.
Sjouke B; Balak DM; Beuers U; Ratziu V; Stroes ES
Curr Opin Lipidol; 2013 Aug; 24(4):301-6. PubMed ID: 23759796
[TBL] [Abstract][Full Text] [Related]
2. Mipomersen as a potential adjunctive therapy for hypercholesterolemia.
Patel N; Hegele RA
Expert Opin Pharmacother; 2010 Oct; 11(15):2569-72. PubMed ID: 20707601
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of mipomersen sodium (Kynamro).
Hovingh K; Besseling J; Kastelein J
Expert Opin Drug Saf; 2013 Jul; 12(4):569-79. PubMed ID: 23611600
[TBL] [Abstract][Full Text] [Related]
4. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.
Raal FJ; Santos RD; Blom DJ; Marais AD; Charng MJ; Cromwell WC; Lachmann RH; Gaudet D; Tan JL; Chasan-Taber S; Tribble DL; Flaim JD; Crooke ST
Lancet; 2010 Mar; 375(9719):998-1006. PubMed ID: 20227758
[TBL] [Abstract][Full Text] [Related]
5. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease.
Stein EA; Dufour R; Gagne C; Gaudet D; East C; Donovan JM; Chin W; Tribble DL; McGowan M
Circulation; 2012 Nov; 126(19):2283-92. PubMed ID: 23060426
[TBL] [Abstract][Full Text] [Related]
6. Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia.
Bell DA; Hooper AJ; Watts GF; Burnett JR
Vasc Health Risk Manag; 2012; 8():651-9. PubMed ID: 23226021
[TBL] [Abstract][Full Text] [Related]
7. Lomitapide and mipomersen: novel lipid-lowering agents for the management of familial hypercholesterolemia.
Dixon DL; Sisson EM; Butler M; Higbea A; Muoio B; Turner B
J Cardiovasc Nurs; 2014; 29(5):E7-E12. PubMed ID: 24231894
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic potential of mipomersen in the management of familial hypercholesterolaemia.
Gelsinger C; Steinhagen-Thiessen E; Kassner U
Drugs; 2012 Jul; 72(11):1445-55. PubMed ID: 22799743
[TBL] [Abstract][Full Text] [Related]
9. Pediatric experience with mipomersen as adjunctive therapy for homozygous familial hypercholesterolemia.
Raal FJ; Braamskamp MJ; Selvey SL; Sensinger CH; Kastelein JJ
J Clin Lipidol; 2016; 10(4):860-869. PubMed ID: 27578117
[TBL] [Abstract][Full Text] [Related]
10. The potential of mipomersen, an ApoB synthesis inhibitor, to reduce necessity for LDL-apheresis in patients with heterozygous familial hypercholesterolemia and coronary artery disease.
Vogt A; Parhofer KG
Expert Opin Pharmacother; 2013 Apr; 14(6):691-7. PubMed ID: 23477485
[TBL] [Abstract][Full Text] [Related]
11. Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia.
Rader DJ; Kastelein JJ
Circulation; 2014 Mar; 129(9):1022-32. PubMed ID: 24589695
[No Abstract] [Full Text] [Related]
12. Mipomersen, an antisense apolipoprotein B synthesis inhibitor.
Bell DA; Hooper AJ; Burnett JR
Expert Opin Investig Drugs; 2011 Feb; 20(2):265-72. PubMed ID: 21210756
[TBL] [Abstract][Full Text] [Related]
13. Apolipoprotein B synthesis inhibition: results from clinical trials.
Visser ME; Kastelein JJ; Stroes ES
Curr Opin Lipidol; 2010 Aug; 21(4):319-23. PubMed ID: 20508521
[TBL] [Abstract][Full Text] [Related]
14. Mipomersen and lomitapide: Two new drugs for the treatment of homozygous familial hypercholesterolemia.
Gouni-Berthold I; Berthold HK
Atheroscler Suppl; 2015 May; 18():28-34. PubMed ID: 25936301
[TBL] [Abstract][Full Text] [Related]
15. Balancing Low-density Lipoprotein Cholesterol Reduction and Hepatotoxicity With Lomitapide Mesylate and Mipomersen in Patients With Homozygous Familial Hypercholesterolemia.
Won JI; Zhang J; Tecson KM; McCullough PA
Rev Cardiovasc Med; 2017; 18(1):21-28. PubMed ID: 28509890
[TBL] [Abstract][Full Text] [Related]
16. Mipomersen: a safe and effective antisense therapy adjunct to statins in patients with hypercholesterolemia.
Ricotta DN; Frishman W
Cardiol Rev; 2012; 20(2):90-5. PubMed ID: 22293857
[TBL] [Abstract][Full Text] [Related]
17. Two new drugs for homozygous familial hyperchelesterolemia.
Med Lett Drugs Ther; 2013 Apr; 55(1413):25-7. PubMed ID: 23545581
[No Abstract] [Full Text] [Related]
18. Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis (The MICA-Study).
Waldmann E; Vogt A; Crispin A; Altenhofer J; Riks I; Parhofer KG
Atherosclerosis; 2017 Apr; 259():20-25. PubMed ID: 28279833
[TBL] [Abstract][Full Text] [Related]
19. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy.
McGowan MP; Tardif JC; Ceska R; Burgess LJ; Soran H; Gouni-Berthold I; Wagener G; Chasan-Taber S
PLoS One; 2012; 7(11):e49006. PubMed ID: 23152839
[TBL] [Abstract][Full Text] [Related]
20. Emerging LDL therapies: Mipomersen-antisense oligonucleotide therapy in the management of hypercholesterolemia.
Toth PP
J Clin Lipidol; 2013; 7(3 Suppl):S6-10. PubMed ID: 23642326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]